EVT-101, also known as ENS-101, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as a selective NMDA receptor subunit 2B (NR2B) antagonist.[1][2] The drug was first claimed by Roche in 2002.[3] By 2017, EVT-101 was in phase II clinical trials for major depressive disorder; however, development of the drug was discontinued in 2021.[1]

See also

References

  1. ^ a b c "EVT 101 - AdisInsight".
  2. ^ "Archived copy" (PDF). Archived from the original (PDF) on 2017-08-29. Retrieved 2018-02-10.{{cite web}}: CS1 maint: archived copy as title (link)
  3. ^ Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC (2012). "Novel NMDA receptor modulators: an update". Expert Opin Ther Pat. 22 (11): 1337–52. doi:10.1517/13543776.2012.728587. PMC 3677696. PMID 23009122.


Allikas: https://en.wikipedia.org/wiki/EVT-101
No tags for this post.